VIDEO: Palliative care referrals critical in end-stage liver disease

ByPaul Kwo, MD

ByMarley V. Ghizzone

Fact checked byHeather Biele

PHILADELPHIA — In this video, Paul Kwo, MD, professor of medicine and director of hepatology at Stanford University, speaks with Healio about the underutilization of palliative care for patients with end-stage liver disease.

Findings from a database analysis study, which evaluated the effect of palliative care consultation on 30- and 90-day readmissions, were presented at the ACG Annual Scientific Meeting.

“Palliative care consults, when obtained, actually reduce readmission rates, and so this is an important aspect of care,” Kwo said. “It may be that over time, we may need to incorporate quality measures that will allow us to better consider and refer appropriate patients for palliative care.”

Reference:

Akhras A, et al. Evaluating the impact of palliative care consultation on 30- and 90-day readmissions among patients with decompensated cirrhosis: A national perspective. Presented at: ACG Annual Scientific Meeting; Oct. 25-30, 2024; Philadelphia (hybrid meeting).

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interviews

Disclosures: Kwo reports serving as an advisor or review panel member for AbbVie; an advisory committee or board member for Aligos, Drug Farm, Gilead and Inventiva; receiving grant or research support from Altimmune, Fractyl, Gilead, Inventiva, Madrigal, Novo Nordisk, Target Registries and Ultragenyx; serving as a consultant for Durect, HepQuant, PPD and Surrozen; and owning stock options in Durect..

Discoveries in Liver

Read more

VIDEO: Palliative care referrals critical in end-stage liver disease

Reference:

Related Content